Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + paclitaxel + vinorelbine
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A chemotherapy combination regimen consisting of 5-fluorouracil (5-FU) administered as continuous infusion, paclitaxel, and vinorelbine. This combination has been studied primarily for the treatment of metastatic breast cancer in patients previously treated with anthracyclines. The regimen leverages the different mechanisms of action of these three drugs to potentially enhance antitumor activity.
02
Targets
DNA polymerase familyPol III (Dna-directed RNA polymerase III)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on fluorouracil + paclitaxel + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + paclitaxel + vinorelbine.